InMode (INMD) Q1 2026: North America Drives 5% Growth as Gross Margin Narrows to 75%
InMode posted modest top-line growth in Q1 2026, driven by a revitalized North American sales force and new laser platforms, but gross margin compression and rising operating expenses signal a more competitive and costly growth environment. Leadership emphasized early stabilization in core geographies and ongoing capital return, yet margin dilution and mixed international trends demand scrutiny as the company pivots to broaden its product and geographic reach.
Summary
- North American Sales Overhaul: Unified structure and leadership refresh are yielding early momentum but require sustained proof.
- Laser Portfolio Expansion: New platforms broaden addressable market but dilute gross margin and add operational complexity.
- Margin Pressure Persists: Cost inflation and salesforce investment continue to weigh on profitability despite revenue gains.
Business Overview
InMode designs, manufactures, and sells energy-based medical devices for aesthetic and medical treatments, generating revenue primarily through direct sales and distributor partnerships. Its business is split between North America and International markets, with product lines focused on minimally invasive platforms (77% of Q1 revenue), laser systems, and emerging segments like ophthalmology via its Envision platform, which targets optometrists and ophthalmologists. The company’s model leverages a global salesforce—298 direct reps and 73 distributors—to drive growth across more than 100 countries.
Performance Analysis
InMode delivered 5% year-over-year revenue growth in Q1 2026, reaching $82 million, with North America leading the rebound following a strategic sales reorganization and new leadership appointments at the close of 2025. International sales contributed 48% of total revenue, up only 2.65% year-over-year, reflecting continued strength in Europe but mixed results in Asia and nascent progress in recently established subsidiaries like Argentina and Thailand.
Gross margin compressed to 75% (GAAP), down from 78% a year ago, as new laser platforms (notably Pico and CO2 systems) expanded procedural breadth but carried lower profitability. Operating expenses climbed 13.7% year-over-year, driven by headcount expansion, sales restructuring, and higher commissions. Non-GAAP operating margin dropped to 17% from 23% in Q1 2025, and diluted EPS declined on both GAAP and non-GAAP bases. Despite margin pressure, InMode generated $15.4 million in operating cash flow and returned $52.7 million to shareholders via buybacks in 2026, supported by a robust $537 million cash balance.
- Salesforce Investment: Higher sales and marketing costs reflect both expanded direct sales teams and restructuring, especially in North America.
- Product Mix Shift: New laser platforms are broadening the offering but are less accretive to margins, a trend likely to persist as more products launch.
- International Expansion: Direct subsidiary buildouts in Argentina and China are in early stages, with regulatory and operational ramp-up ongoing.
Overall, InMode is balancing top-line growth with margin headwinds and continued investment in global reach and product breadth, setting the stage for longer-term competitive positioning but with near-term profitability tradeoffs.
Executive Commentary
"We have transitioned from our longstanding east-west structure to unify North American model, bringing Canada and both coasts under the same organization. This is driving better coordination and clearer accountability."
Moshe Mizrachi, Chief Executive Officer
"Gross margin in the first quarter of 2026 was 75% on a GAAP basis compared to 78% in the first quarter of 2025...This decrease was primarily attributable to the increase in cost of goods and, as mentioned before, the new structure of the North America sales team implemented towards the end of 2025 and subsidiary establishments in the later part of 2025."
Yair Malka, Chief Financial Officer
Strategic Positioning
1. North American Model Unification
InMode’s shift to a unified North American sales structure, consolidating Canada and both U.S. coasts under one organization, is intended to drive greater coordination and accountability. Early signs of improved momentum emerged in March, but leadership remains cautious, seeking sustained consistency before declaring success.
2. Laser Platform Expansion
Recent launches of Pico and CO2 laser systems have expanded InMode’s addressable procedure range, positioning the company as a “one-stop-shop” for physicians seeking comprehensive solutions. However, these platforms have a dilutive effect on gross margins and require ongoing regulatory and R&D investment—especially as the company develops proprietary versions for global markets.
3. International Direct Subsidiary Buildout
New subsidiaries in Argentina and China reflect a strategic pivot toward direct market entry, bypassing distributors where feasible. The Argentina operation is now regulatory-ready and expected to contribute sales beginning in Q2 2026, while China’s subsidiary is being repurposed for the spa and cosmetic segment, with a differentiated product line under development.
4. Focused Sales Teams for Niche Segments
The Envision ophthalmology/optometry platform now has a dedicated U.S. sales team, marking the first time InMode has separated a single product for specialized focus. Early performance is promising, but management is waiting for more data before expanding this model to other products.
5. Capital Allocation Flexibility
With over $537 million in cash, InMode is actively returning capital via buybacks (over $600 million in six years) while remaining open to M&A, dividends, and other shareholder return mechanisms. Management acknowledges that buybacks alone have not supported the share price and is exploring broader capital allocation strategies.
Key Considerations
This quarter marks a transitional phase for InMode, where operational restructuring and new product launches are reshaping both revenue streams and cost structure. The company is navigating a more competitive, innovation-driven market while contending with margin and cost headwinds.
Key Considerations:
- Salesforce Realignment Impact: Early signs of improved U.S. performance are encouraging, but consistency and scalability remain unproven.
- Gross Margin Dilution from New Products: Laser platform expansion is strategically necessary but will continue to pressure profitability.
- International Execution Risk: Subsidiary launches in Argentina and China are in early stages; successful ramp will be critical for geographic diversification.
- Capital Allocation Strategy in Flux: Management is signaling openness to M&A and dividends as buybacks alone have not driven share price appreciation.
- Leadership Transition: CFO transition introduces uncertainty around financial stewardship and may affect capital allocation discipline in the near term.
Risks
Gross margin compression, driven by product mix and higher sales costs, may persist as InMode invests in new platforms and global expansion. International execution risk is heightened as new subsidiaries ramp, with regulatory and operational hurdles in emerging markets. Leadership transitions, especially in the CFO role, introduce potential for shifts in financial discipline and capital allocation. Competitive intensity from both energy-based and injectable aesthetic solutions continues to threaten share of wallet.
Forward Outlook
For Q2 2026, InMode guided to:
- Continued revenue growth driven by North America and initial contributions from new subsidiaries
- Gross margin in the 74% to 76% range (non-GAAP)
For full-year 2026, management maintained guidance:
- Revenue of $365 million to $375 million
- Non-GAAP operating income of $73 million to $78 million
- Non-GAAP diluted EPS of $1.33 to $1.38
Management cited stabilization in core markets, ongoing product launches, and capital allocation flexibility as key factors for the year:
- Laser platform launches and geographic expansion are expected to drive incremental growth, but margin pressure will remain a focus.
- Buybacks will continue, but M&A and alternative return strategies are under consideration.
Takeaways
InMode’s Q1 2026 results underscore a business in strategic transition, with operational restructuring and product innovation driving revenue gains at the expense of margin. Investors should watch for evidence of sustained salesforce effectiveness, successful international subsidiary ramp, and capital allocation discipline as the company navigates a more competitive and cost-intensive market.
- Margin Watch: Persistent gross margin compression highlights the tradeoff between growth and profitability as new product lines expand.
- Sales Structure in Focus: Early U.S. sales improvements require sustained execution to validate the new model’s scalability.
- International Ramp: Execution in Argentina and China will be key to long-term diversification and growth, but near-term contribution is uncertain.
Conclusion
InMode is leveraging operational changes and product innovation to drive modest growth, but faces mounting cost and margin pressures as it broadens its global and procedural footprint. The next quarters will test the durability of recent sales improvements and the company’s ability to balance expansion with disciplined profitability and capital deployment.
Industry Read-Through
InMode’s experience this quarter reflects a broader trend in the aesthetic device sector: Growth increasingly requires both innovation and operational agility, but often at the expense of traditional margin structures. The competitive threat from injectables and alternative therapies is intensifying, forcing device manufacturers to pursue more integrated, “one-stop-shop” solutions. International expansion is a common theme, yet regulatory and operational complexity remain real barriers. Capital allocation is under scrutiny across the sector, with many public players rethinking buybacks and exploring M&A for scale or portfolio breadth. Investors in medical device and aesthetics should expect continued margin volatility and a premium on execution as the industry evolves.